Loading…
Altimmune, Inc. is projected to rise to $4.03 by 2027, a +35% move from its current price of $2.98. ALT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.88 | $2.98 | $3.08 | +0.03% |
| May 30 | $2.85 | $2.98 | $3.12 | +0.06% |
| May 31 | $2.82 | $2.98 | $3.16 | +0.09% |
| Jun 1 | $2.79 | $2.98 | $3.19 | +0.12% |
| Jun 2 | $2.77 | $2.98 | $3.21 | +0.15% |
| Jun 3 | $2.75 | $2.99 | $3.24 | +0.18% |
| Jun 4 | $2.74 | $2.99 | $3.26 | +0.21% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.74 | $2.99 | $3.26 | +0.21% |
| Week 2 | $2.64 | $2.99 | $3.39 | +0.43% |
| Week 3 | $2.58 | $3.00 | $3.49 | +0.64% |
| Week 4 | $2.52 | $3.01 | $3.58 | +0.86% |
| Week 5 | $2.48 | $3.01 | $3.66 | +1.08% |
| Week 6 | $2.44 | $3.02 | $3.74 | +1.29% |
| Week 7 | $2.40 | $3.02 | $3.81 | +1.51% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Altimmune, Inc. is a healthcare company described as a late clinical stage biopharmaceutical company focused on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
ALT is a healthcare stock currently trading at $2.90 per share with a market capitalization of $563.98M. The stock is ranked 2949. The 30-day range sits between $2.30 and $3.65, with a current setup that includes support at $2.60 and resistance at $3.56. The 50-day simple moving average is $3.15 and the 200-day simple moving average is $3.96.
Forecasts indicate a path toward higher prices over time, beginning with 2026 showing a neutral stance (min $2.60, avg $2.90, max $4.26). From 2027 onward, the outlook shifts to bullish with rising averages through 2033–2050, including 2030 avg $4.72 and 2050 avg $14.87, suggesting meaningful upside potential compared with the current level.
A major floor 30.0% below — a decisive break under it would weaken the trend.
The nearest floor, 12.8% below — buyers have tended to step in here.
The nearest ceiling, 19.5% above — a clean break opens room to run.
A major ceiling 107.4% above — clearing it would confirm fresh momentum.
Key ALT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ALT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.91 | Buy | $2.92 | Buy |
| MA 10 | $2.89 | Buy | $2.92 | Buy |
| MA 20 | $2.93 | Buy | $2.96 | Buy |
| MA 50 | $3.13 | Sell | $3.21 | Sell |
| MA 100 | $3.79 | Sell | $3.57 | Sell |
| MA 200 | $3.96 | Sell | $4.03 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.49 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 26.54 | Neutral |
| Williams %R (14) | -31.43 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -3.56 | Sell |
| Bollinger %B (20,2) | 0.58 | Neutral |
| Stochastic %K (14) | 68.57 | Neutral |
| TRIX (15) | -0.44 | Sell |
| Awesome (5,34) | -0.14 | Sell |
| Ultimate (7,14,28) | 53.32 | Neutral |
| Momentum (10) | -0.10 | Sell |
| Aroon Osc (25) | -24.00 | Sell |
| Hull MA (9) | 2.96 | Buy |
| ADX (14) | 14.79 | Neutral |
| ATR (14) | 0.08 | Info |
The near-term technical picture is NEUTRAL with an RSI of 40. Price action is confined around the current area, with a 30-day range of $2.30 to $3.65. The stock sits between a support level of $2.60 and a resistance level of $3.56, while the 50-day and 200-day moving averages stand at $3.15 and $3.96 respectively.
Annualized volatility is 70%, indicating elevated price swings relative to a typical equity profile.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.60 | $2.98 | $4.31 | 0% | Neutral | |
| $3.13 | $4.03 | $5.52 | +35% | Bullish | |
| $3.52 | $4.68 | $6.70 | +57% | Bullish | |
| $3.26 | $4.47 | $6.61 | +50% | Bullish | |
| $3.39 | $4.76 | $7.23 | +60% | Bullish | |
| $3.39 | $4.88 | $7.60 | +64% | Bullish | |
| $3.16 | $4.64 | $7.39 | +56% | Bullish | |
| $4.15 | $6.22 | $10.10 | +109% | Bullish | |
| $4.62 | $7.07 | $11.68 | +137% | Bullish | |
| $4.32 | $6.73 | $11.32 | +126% | Bullish | |
| $5.70 | $9.69 | $17.47 | +225% | Bullish | |
| $7.55 | $14.95 | $29.81 | +402% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.60 | $2.98 | $3.49 | +0.00% |
| June 2026 | $2.53 | $2.99 | $3.62 | +0.20% |
| July 2026 | $2.57 | $3.06 | $3.77 | +2.62% |
| August 2026 | $2.50 | $3.00 | $3.74 | -2.00% |
| September 2026 | $2.50 | $3.02 | $3.81 | +0.70% |
| October 2026 | $2.67 | $3.24 | $4.12 | +7.25% |
| November 2026 | $2.75 | $3.36 | $4.31 | +3.74% |
| December 2026 | $2.72 | $3.34 | $4.31 | -0.62% |
Click any year to see its month-by-month ALT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Altimmune, Inc.'s 2026 outlook centres on $2.98, within a $2.60 to $4.31 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ALT could reach as high as $5.52, with a base case around $4.03 and support toward $3.13 — roughly +35% from $2.98. Buyers look set to stay in control over this stretch.
Expect ALT to range from $3.52 to $6.70 through 2028. The $4.68 average target implies a +57% move from current prices. That is up +16% on the projected 2027 average. Momentum favours further upside here.
The ALT price prediction for 2029 points to an average of $4.47 (low $3.26, high $6.61) — a potential gain of +50% on today's $2.98. Buyers look set to stay in control over this stretch.
In 2030, ALT is projected to trade between $3.39 and $7.23, averaging $4.76 — a potential gain of +60% from today's $2.98. That is up +6% on the projected 2029 average. Momentum favours further upside here.
Altimmune, Inc.'s 2031 outlook centres on $4.88, within a $3.39 to $7.60 range. That is up +3% on the projected 2030 average. That marks a +64% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, ALT could reach as high as $7.39, with a base case around $4.64 and support toward $3.16 — roughly +56% from $2.98. Momentum favours further upside here.
Expect ALT to range from $4.15 to $10.10 through 2033. The $6.22 average target implies a +109% move from current prices. That is up +34% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ALT price prediction for 2034 points to an average of $7.07 (low $4.62, high $11.68) — a potential gain of +137% on today's $2.98. Momentum favours further upside here.
In 2035, ALT is projected to trade between $4.32 and $11.32, averaging $6.73 — a potential gain of +126% from today's $2.98. That is -5% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
Altimmune, Inc.'s 2040 outlook centres on $9.69, within a $5.70 to $17.47 range. That is up +44% on the projected 2035 average. That marks a +225% change versus current levels. Momentum favours further upside here.
By 2050, ALT could reach as high as $29.81, with a base case around $14.95 and support toward $7.55 — roughly +402% from $2.98. Buyers look set to stay in control over this stretch.
Investing $1,000 in ALT today (≈ 335.57047 ALT) could be worth
$5,015.74
+$4,015.74 (+402%) by 2050 · US Dollar
Based on the average projected ALT price of $14.95 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ALTwould be worth at today's price.
$1,000 invested in ALT on May 27, 2025 (≈ 181.488196 ALT) would be worth
$540.83
-$459.17 (-45.9%) today · 0.54× · US Dollar
Based on a ALT entry price of $5.51 vs. today's $2.98.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.82 | $1,056.74 | +5.7% |
| 1 month ago | $2.8 | $1,064.29 | +6.4% |
| 3 months ago | $4.46 | $668.16 | -33.2% |
| 6 months ago | $5.26 | $566.54 | -43.3% |
| 1 year ago | $5.51 | $540.83 | -45.9% |
| All time (5.0y) ago | $12.46 | $239.17 | -76.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ALT forecast.
Our base-case forecast reaches $6.00 around 2033.
Implied market cap at $6.00: $1.17B
The multi-year forecast shows a bullish trend taking hold after 2026. The 2026 forecast is neutral with min $2.60, avg $2.90, max $4.26. From 2027 onward, the Avg price climbs to $4.00 (2027), $4.63 (2028), $4.41 (2029), $4.72 (2030), $4.79 (2031), $4.56 (2032), $6.26 (2033), $7.05 (2034), and $6.65 (2035).
By 2040, the Avg is $9.65 and by 2050 the Avg reaches $14.87, with the Max hitting as high as $17.75 in 2040 and $30.35 in 2050.
Across these years, the implied ROI rises from 0 in 2026 to 37.9 in 2027, 59.7 in 2028, 52.2 in 2029, 62.8 in 2030, 65.1 in 2031, 57.2 in 2032, 115.8 in 2033, 143.1 in 2034, 129.3 in 2035, 232.8 in 2040, and 412.7 in 2050. The sentiment shifts to BULLISH from 2027 onward, reflecting an increasingly favorable outlook among the model’s projections.
These figures are estimates and not guarantees. They illustrate a potential path for ALT under the provided assumptions and should be considered in the context of inherent market and sector risks.
Tap a question to reveal the answer.
Avg $4.72, Max $7.28, ROI 62.8, sentiment BULLISH.
The forecast shows a bullish sentiment from 2027 onward with rising averages and ROI through 2050, though 2026 is Neutral and these are estimates, not guarantees.
Yes, the 2033 forecast max is $10.32 and the 2034 max is $11.85, indicating potential to exceed $10 in the projection horizon.
Avg $9.65, Max $17.75, ROI 232.8, sentiment BULLISH.
Avg $14.87, Max $30.35, ROI 412.7, sentiment BULLISH.
Altimmune, Inc. Community Discussion
0Share your Altimmune, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.